"One Injection to Regenerate Cartilage"... Big Move Ventures Bets on YiPSCELL [fn Market Watch]

[Financial News] Big Move Ventures, a venture capital firm affiliated with Bumin Hospital Group, is investing in YiPSCELL, a regenerative medicine company based on induced pluripotent stem cells (iPSCs). YiPSCELL is developing a treatment for osteoarthritis that aims to regenerate cartilage with a single injection. The investment reflects a favorable assessment of YiPSCELL's technology and its potential to benefit from the revised Advanced Regenerative Bio Act.
According to investment banking industry sources on the 5th, the 2026 KIF Future Growth AI Investment Fund, jointly managed by Big Move Ventures and Korea Investment Partners, recently decided to invest in YiPSCELL.
The Korea Fund of Funds and KIF (Korea IT Fund) each contributed 10 billion won to the fund. Indang Medical Foundation and the two asset managers also participated as investors.
The round is worth 12 billion won and will be carried out through YiPSCELL's issuance of new redeemable convertible preferred shares (RCPS). InterVest, HB Investment, AJU IB Investment, Premier Partners, and Korea Venture Investment each invested 2 billion won, while FuturePlay and Big Move Ventures each invested 1 billion won. InterVest and FuturePlay have already completed their payments, while the remaining investors are scheduled to make their payments this month. The redemption right may be exercised beginning five years after the investment, and the redemption rate is 6% compounded annually.
iPSCs are cells created by reprogramming fully developed somatic cells into a state similar to that of embryonic stem cells. Shinya Yamanaka received the 2012 Nobel Prize in Physiology or Medicine for this technology. Because iPSCs can differentiate into all types of cells, they are considered an alternative that could overcome the differentiation limitations of adult stem cells and the problem of cellular aging. However, the risk that undifferentiated cells may form tumors and the difficulty of mass production have been cited as obstacles to commercialization.
YiPSCELL's flagship pipeline, YL111 (MIUChon), involves injecting three-dimensional cartilage organoids derived from iPSCs into the joint cavity. The company says it controlled the undifferentiated stem cells to eliminate the risk of tumor formation and established manufacturing and quality control (CMC) standards at its own GMP facility. Safety was confirmed in a domestic investigator-initiated clinical study involving three patients, and early efficacy signals were observed in pain measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS).
Market demand is clear. Existing anti-inflammatory painkillers and hyaluronic acid injections only relieve pain, while current cartilage-regenerating cell therapies require an incision or microfracture surgery. As a result, patients with moderate Kellgren-Lawrence (K&L) Classification grades 2–3 have few suitable treatment options.
The regulatory environment is also favorable. Under the revised Advanced Regenerative Bio Act, which took effect last February, treatments whose safety and efficacy have been confirmed through clinical research may be administered at medical institutions as advanced regenerative medicine treatments even before receiving approval. YiPSCELL plans to use the system to generate early out-of-pocket revenue.
The approach is expected to reduce the cash-flow gap during the research and development period, a weakness often associated with biotech companies. YiPSCELL also aims to generate revenue by distributing cell lines and providing contract development and manufacturing organization (CDMO) services in the disease-modeling market, which has been expanding since the U.S. FDA Modernization Act 2.0 allowed alternatives to animal testing.
Meanwhile, YiPSCELL plans to enter a clinical trial under Japan's Pharmaceuticals and Medical Devices Agency (PMDA) between this year and next year. After completing data collection this year from its main clinical trial involving 30 patients, the company plans to undergo a technology evaluation and pursue a KOSDAQ (Korea Securities Dealers Automated Quotations) listing in 2027.

[email protected] Kang Gu-gwi Reporter